Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings (NYSE:ABT)

Date:

Share post:


MCCAIG

In my previous Abbott Laboratories (NYSE:ABT) article, I discussed the company’s Q3 2023 earnings, revealing a significant resurgence in their primary business segments. The decline in COVID-19 testing-related revenue did not stop Abbott from pulling in $10.1B for the quarterreportedApril 17th

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Amazon’s Fake Book Problem With Upcoming UFO Tome ‘Imminent’

The former senior leader of a Pentagon unit that studied UFOs...

Gorilla Technology Group Gains Momentum With $2 Billion Pipeline

This article was written byFollowThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased,...

MS Project 2024 — Your Project Partner for Life

Disclosure: Our goal is to feature products...

20 Signs of a Fake Job Interview

Editor's Note: This story originally appeared on FlexJobs.com.Let’s say you applied for a job and are now...